Drug intelligence / Profile preview

ATL-003

Development stage: Preclinical
Lead developer: Atlas Molecular Pharma
Modality: Targeted Protein Degraders (TPDs) → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules

Overview

ATL-003 is a small molecule pharmacological allosteric chaperone developed by Atlas Molecular Pharma. It is designed using the Chassys platform, which leverages NMR-based technology to identify and optimize compounds that modulate protein folding and function. The drug acts as a protein modulator, with its primary research focus on neurodegenerative disorders, particularly prion diseases. As of the latest updates, ATL-003 remains in preclinical development and has not yet advanced to clinical trials[1][2].

Targets

PrPSc (Major prion protein)

Beyond the preview

Go deeper on ATL-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATL-003.

Explore the full profile